Heron Therapeutics, Inc. (HRTX – Snapshot Report) announced positive, top-line data from a phase II study on HTX-011 for the management of post-operative pain in patients undergoing bunionectomy. The candidate is developed using Heron’s proprietary Biochronomer drug delivery technology. We expect investors to react positively to the news.
The randomized, placebo-controlled, double-blind, phase II study compared the efficacy and safety of HTX-011, containing 200 mg or 400 mg of bupivacaine (local anesthetic) and meloxicam (anti-inflammatory drug), to placebo. The study met its primary endpoint of demonstrating statistically significant difference as compared to placebo in pain intensity as measured by the summed pain intensity score in the first 24 hours post-surgery. The study also met all key secondary endpoints with a high degree of statistical significance. The candidate was well tolerated in the study.
The current standard of care for post-operative pain management, opioid analgesics, is associated with side effects that lead to increased hospitalization and recovery time. HTX-011, if successfully developed and eventually approved, has the potential to reduce dependence on post-operative opioids.
Heron Therapeutics is yet to have a product approved. The lead candidate in the company’s pipeline, Sustol, is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy or highly emetogenic chemotherapy. The candidate is currently under FDA review with a decision expected by Jan 17, 2016.
Heron Therapeutics currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Gilead Sciences Inc. (GILD – Analyst Report), Regeneron Pharmaceuticals, Inc. (REGN – Analyst Report) and Valeant Pharmaceuticals International, Inc. (VRX – Analyst Report). Both Gilead and Regeneron hold a Zacks Rank #1 (Strong Buy), while Valeant is a Zacks Rank #2 (Buy) stock. – See more at:
Related Posts
FTSE 100 Remains Stable After Friday’s NFP Report
5 Of Friday’s Biggest Marijuana Stock Gainers
Market Talk – November 27, 2015
AstraZeneca And Takeda Pharmaceutical Company Limited Parkinson’s Collaboration- The Death Of Cash – New Tech To Revolutionize The Payments Industry (SPONSORED POST)
US Equity Futures Suddenly Fall Off A Cliff As Europe Slides, Oil Tumbles, EM Currencies Turmoil
Leave A Comment